Prostate cancer (PCa), the second most common cancer affecting men worldwide, shows a broad spectrum of biological and clinical behaviour representing the epiphenomenon of an extreme heterogeneity. Androgen deprivation therapy is the mainstay of treatment for advanced forms but after few years the majority of patients progress to castration-resistant prostate cancer (CRPC), a lethal form that poses considerable therapeutic challenges.

Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer

FERRARI, NICOLETTA;CAPAIA, MATTEO GINO LINO;Brizzolara, Antonella;Astigiano, Simonetta;Amaro, Adriana Agnese;Boccardo, Francesco;
2017

Abstract

Prostate cancer (PCa), the second most common cancer affecting men worldwide, shows a broad spectrum of biological and clinical behaviour representing the epiphenomenon of an extreme heterogeneity. Androgen deprivation therapy is the mainstay of treatment for advanced forms but after few years the majority of patients progress to castration-resistant prostate cancer (CRPC), a lethal form that poses considerable therapeutic challenges.
File in questo prodotto:
File Dimensione Formato  
12964_2017_Article_206.pdf

accesso aperto

Tipologia: Documento in versione editoriale
Dimensione 4.32 MB
Formato Adobe PDF
4.32 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11567/886253
Citazioni
  • ???jsp.display-item.citation.pmc??? 13
  • Scopus 19
  • ???jsp.display-item.citation.isi??? 19
social impact